Article Text

Download PDFPDF
Drug misuse in pregnancy: losing sight of the baby?
  1. L McGlone1,
  2. H Mactier1,
  3. L T Weaver2
  1. 1
    Neonatal Unit, Princess Royal Maternity, Glasgow, UK
  2. 2
    Department of Child Health, University of Glasgow, Glasgow, UK
  1. Correspondence to Dr L McGlone, Neonatal Unit, Princess Royal Maternity, 8–16 Alexandra Parade, Glasgow G31 2ER, UK; lauramcglone{at}


Maternal drug misuse can seriously affect the health of the fetus and newborn infant. The association of maternal drug misuse with prematurity, intrauterine growth restriction (IUGR) and neonatal abstinence syndrome (NAS) is well recognised, and there is growing concern about infant visual development and longer-term neurodevelopmental outcome. Drug misuse is associated with changes in the visual system as measured by the visual evoked potential (VEP) in adults and animal models. A recent study has shown abnormal VEPs in newborn infants exposed to methadone in utero, consistent with reports of delayed visual development in this population. Since visual abnormalities and neurodevelopmental abnormalities can be predicted by abnormal VEPs in infancy, it is postulated that the VEP may be a valuable tool in the detection of the adverse effects of maternal drug misuse upon the infant. This review summarises the impact of maternal drug misuse upon the health of the fetus and newborn infant, addresses the specific effects of maternal drug misuse upon the developing visual system and discusses the potential role of the VEP in the assessment of these infants.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding LMcG is funded by the Yorkhill Children’s Foundation.

  • Competing interests None.